13. (Amended). The use of claim 8, wherein the medicament is for the prevention of apoptosis following an ischaemic-reperfusion injury.

14. (Amended). The use of claim 8 wherein the medicament further comprises one or more of:

(a) adenosine or purine or a precursor thereof;

(b) ribose;

(c) nicotinamide or derivatives thereof;

(d) a Ca^{2+} ion uptake inhibitor;

(e) a cardioplegic solution;

(f) means to maintain the glutathione system, such as glutathione peroxidase and the reduced form of glutathione (GSH); or,

(g) an endothelin inhibitor.

15. (Amended). An in vitro method for preserving an organ for transplantation, the method comprising contacting the organ with a composition of claim 1.

REMARKS

The Applicant has made corrections to claims in order to conform to U.S. practice and no new matter is introduced by the amendment

CONCLUSION

If the Examiner believes a telephone conference would expedite prosecution of this application, please telephone the undersigned at 510-337-7871.

LAW OFFICES OF
JONATHAN ALAN QUINE
P.O. BOX 458
Alameda, CA 94501
(510) 337-7871
Fax (510) 337-7877

Respectfully submitted,

Jonathan Alan Quine, J.D., Ph.D.
Reg. No. 41.261

Marked Copy of Amended Claims for U.S. National Phase of PCT/GB99/01499

1. A composition comprising an inositolphosphoglycan (IPG) or an IPG synthetic analogue and ribose.

2. The composition of claim 1 wherein the IPG is a P-type IPG.

3. The composition of claim 1 wherein the synthetic analogue is a P-type IPG synthetic analogue.

4. The composition of **[any one of the preceding claims]** **claim 1**, further comprising adenosine or purine, or a nucleotide precursor thereof.

5. The composition of claim 1 or claim 2, wherein the composition is a liquid composition.

6. The composition of claim 1 or claim 2, wherein the composition is a powder or concentrate from which a liquid composition can be prepared.

7. A composition of **[any one the preceding claims] claim 1** for use in a method of medical treatment.

8. Use of an inositolphosphoglycan (IPG) or an IPG synthetic analogue for the preparation of a medicament for the treatment of an ischaemic-reperfusion injury.

9. The use of claim 8 wherein the IPG is a P-type IPG.

10. The use of claim 8 wherein the synthetic analogue is a P-type IPG synthetic analogue.

11. The use of **[any one of]** claim**[s]** 8 **[to 10]**, wherein the ischaemic-reperfusion injury arises from myocardial infarct, surgery or stroke.

12. The use of claim 11, wherein the surgery is open heart surgery, organ transplantation surgery, or heart or lung bypass surgery

13. The use of **[any one of]** claim**[s]** 8 **[to 12]**, wherein the medicament is for the prevention of apoptosis following an ischaemic-reperfusion injury.

14. The use of **[any one of]** claim**[s]** 8 **[to 13]** wherein the medicament further comprises one or more of:

(a) adenosine or purine or a precursor thereof;
(b) ribose;
(c) nicotinamide or derivatives thereof;
(d) a Ca^{2+} ion uptake inhibitor;
(e) a cardioplegic solution;
(f) means to maintain the glutathione system, such as glutathione peroxidase and the reduced form of glutathione (GSH); or,
(g) an endothelin inhibitor.

15. An in vitro method for preserving an organ for transplantation, the method comprising contacting the organ with a composition of **[any one of]** claim**[s]** 1 **[to 7]**.

16. The method of claim 15 wherein the composition is perfused through the organ.

17. The method of claim 15 wherein the organ is stored in the composition prior to transplantation.

Courtesy Copy of Amended Claims for U.S. National Phase of PCT/GB99/01499

1. A composition comprising an inositolphosphoglycan (IPG) or an IPG synthetic analogue and ribose.

2. The composition of claim 1 wherein the IPG is a P-type IPG.

3. The composition of claim 1 wherein the synthetic analogue is a P-type IPG synthetic analogue.

4. The composition of claim 1, further comprising adenosine or purine, or a nucleotide precursor thereof.

5. The composition of claim 1 or claim 2, wherein the composition is a liquid composition.

6. The composition of claim 1 or claim 2, wherein the composition is a powder or concentrate from which a liquid composition can be prepared.

7. A composition of claim 1, for use in a method of medical treatment.

8. Use of an inositolphosphoglycan (IPG) or an IPG synthetic analogue for the preparation of a medicament for the treatment of an ischaemic-reperfusion injury.

9. The use of claim 8 wherein the IPG is a P-type IPG.

10. The use of claim 8 wherein the synthetic analogue is a P-type IPG synthetic analogue.

11. The use of claim 8, wherein the ischaemic-reperfusion injury arises from myocardial infarct, surgery or stroke.

12. The use of claim 11, wherein the surgery is open heart surgery, organ transplantation surgery, or heart or lung bypass surgery.

13. The use of claim 8, wherein the medicament is for the prevention of apoptosis following an ischaemic-reperfusion injury.

14. The use of claim 8 wherein the medicament further comprises one or more of:

(a) adenosine or purine or a precursor thereof;
(b) ribose;
(c) nicotinamide or derivatives thereof;
(d) a Ca^{2+} ion uptake inhibitor;

(e) a cardioplegic solution;
(f) means to maintain the glutathione system, such as glutathione peroxidase and the reduced form of glutathione (GSH); or,
(g) an endothelin inhibitor.

15. An in vitro method for preserving an organ for transplantation, the method comprising contacting the organ with a composition of claim 1.

16. The method of claim 15 wherein the composition is perfused through the organ.

17. The method of claim 15 wherein the organ is stored in the composition prior to transplantation.